<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Cytomed Therapeutics Limited Ordinary Shares — News on 6ix</title>
    <link>https://6ix.com/company/cytomed-therapeutics-limited-ordinary-shares</link>
    <description>Latest news and press releases for Cytomed Therapeutics Limited Ordinary Shares on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 28 Jan 2026 15:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/cytomed-therapeutics-limited-ordinary-shares" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835764978dffbe2df0f72aa.webp</url>
      <title>Cytomed Therapeutics Limited Ordinary Shares</title>
      <link>https://6ix.com/company/cytomed-therapeutics-limited-ordinary-shares</link>
    </image>
    <item>
      <title>CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress</title>
      <link>https://6ix.com/company/cytomed-therapeutics-limited-ordinary-shares/news/cytomed-therapeutics-refutes-misleading-claims-150000020</link>
      <guid isPermaLink="true">https://6ix.com/company/cytomed-therapeutics-limited-ordinary-shares/news/cytomed-therapeutics-refutes-misleading-claims-150000020</guid>
      <pubDate>Wed, 28 Jan 2026 15:00:00 GMT</pubDate>
      <description>SINGAPORE, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumors, today issued a statement to address recent statements containing inaccurate and misleading claims regarding the Comp</description>
    </item>
    <item>
      <title>CytoMed Therapeutics’ new year update and seeks shareholders’ feedback on proposal to improve shareholder value for their patient capital</title>
      <link>https://6ix.com/company/cytomed-therapeutics-limited-ordinary-shares/news/cytomed-therapeutics-seeks-shareholders-feedback-130000157</link>
      <guid isPermaLink="true">https://6ix.com/company/cytomed-therapeutics-limited-ordinary-shares/news/cytomed-therapeutics-seeks-shareholders-feedback-130000157</guid>
      <pubDate>Tue, 13 Jan 2026 13:00:00 GMT</pubDate>
      <description>SINGAPORE, Jan. 13, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, is pleased to update shareholders as we enter a new exciting year in 2026. As mentioned in previous announcements,</description>
    </item>
    <item>
      <title>CytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Cells Allogeneic Technology to Treat Cancers in Malaysia</title>
      <link>https://6ix.com/company/cytomed-therapeutics-limited-ordinary-shares/news/cytomed-therapeutics-announces-novel-first-130000587</link>
      <guid isPermaLink="true">https://6ix.com/company/cytomed-therapeutics-limited-ordinary-shares/news/cytomed-therapeutics-announces-novel-first-130000587</guid>
      <pubDate>Mon, 08 Dec 2025 13:00:00 GMT</pubDate>
      <description>SINGAPORE, Dec. 08, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumors, today announced that it has entered into a Memorandum of Understanding with Universiti Malaya Medical Centre (“UMMC”</description>
    </item>
    <item>
      <title>CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India</title>
      <link>https://6ix.com/company/cytomed-therapeutics-limited-ordinary-shares/news/cytomed-therapeutics-completes-acquisition-t-130000548</link>
      <guid isPermaLink="true">https://6ix.com/company/cytomed-therapeutics-limited-ordinary-shares/news/cytomed-therapeutics-completes-acquisition-t-130000548</guid>
      <pubDate>Tue, 18 Nov 2025 13:00:00 GMT</pubDate>
      <description>SINGAPORE, Nov. 18, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary novel technologies to develop affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, announced today that it has completed with full payment the acquisition of the allogeneic gamma delta T cell technology</description>
    </item>
    <item>
      <title>CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy</title>
      <link>https://6ix.com/company/cytomed-therapeutics-limited-ordinary-shares/news/cytomed-therapeutics-secures-non-dilutive-130000538</link>
      <guid isPermaLink="true">https://6ix.com/company/cytomed-therapeutics-limited-ordinary-shares/news/cytomed-therapeutics-secures-non-dilutive-130000538</guid>
      <pubDate>Thu, 06 Nov 2025 13:00:00 GMT</pubDate>
      <description>SINGAPORE, Nov. 06, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, announced today that it secures non-dilutive investment for its subsidiary, LongevityBank Pte Ltd (“LongevityBank”) fro</description>
    </item>
    <item>
      <title>CytoMed Therapeutics’ Chairman Increases Effective Holdings to 21.95%</title>
      <link>https://6ix.com/company/cytomed-therapeutics-limited-ordinary-shares/news/cytomed-therapeutics-chairman-increases-effective-120000999</link>
      <guid isPermaLink="true">https://6ix.com/company/cytomed-therapeutics-limited-ordinary-shares/news/cytomed-therapeutics-chairman-increases-effective-120000999</guid>
      <pubDate>Wed, 22 Oct 2025 12:00:00 GMT</pubDate>
      <description>SINGAPORE, Oct. 22, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, today announced that its Executive Chairman and substantial shareholder, Mr Peter Choo has increased his shareholding i</description>
    </item>
    <item>
      <title>CytoMed makes cash bid for potential acquisition of TC BioPharm Limited’s relevant assets</title>
      <link>https://6ix.com/company/cytomed-therapeutics-limited-ordinary-shares/news/cytomed-makes-cash-bid-potential-120000910</link>
      <guid isPermaLink="true">https://6ix.com/company/cytomed-therapeutics-limited-ordinary-shares/news/cytomed-makes-cash-bid-potential-120000910</guid>
      <pubDate>Tue, 14 Oct 2025 12:00:00 GMT</pubDate>
      <description>SINGAPORE, Oct. 14, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, today announced that it has submitted a cash bid for an undisclosed sum with Michael Magnay and Rob Croxen of Alvarez a</description>
    </item>
    <item>
      <title>CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia</title>
      <link>https://6ix.com/company/cytomed-therapeutics-limited-ordinary-shares/news/cytomed-therapeutics-announces-publication-collaborative-110000996</link>
      <guid isPermaLink="true">https://6ix.com/company/cytomed-therapeutics-limited-ordinary-shares/news/cytomed-therapeutics-announces-publication-collaborative-110000996</guid>
      <pubDate>Thu, 02 Oct 2025 11:00:00 GMT</pubDate>
      <description>SINGAPORE, Oct. 02, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, is pleased to announce the publication of a preclinical study, in a research article entitled “Donor-Derived Vγ9Vδ2 T C</description>
    </item>
    <item>
      <title>CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia </title>
      <link>https://6ix.com/company/cytomed-therapeutics-limited-ordinary-shares/news/cytomed-therapeutics-announces-publication-of-collaborative-research-with-the-university-of-texas-md-anderson-cancer-center-demonstrating-the-potential-of-allogeneic-gd-t-cells-in-acute-myeloid-leukemia</link>
      <guid isPermaLink="true">https://6ix.com/company/cytomed-therapeutics-limited-ordinary-shares/news/cytomed-therapeutics-announces-publication-of-collaborative-research-with-the-university-of-texas-md-anderson-cancer-center-demonstrating-the-potential-of-allogeneic-gd-t-cells-in-acute-myeloid-leukemia</guid>
      <pubDate>Thu, 02 Oct 2025 04:00:00 GMT</pubDate>
      <description>SINGAPORE, Oct. 02, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage</description>
    </item>
    <item>
      <title>Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition</title>
      <link>https://6ix.com/company/cytomed-therapeutics-limited-ordinary-shares/news/recent-acquisition-cytomed-therapeutics-expands-130000542</link>
      <guid isPermaLink="true">https://6ix.com/company/cytomed-therapeutics-limited-ordinary-shares/news/recent-acquisition-cytomed-therapeutics-expands-130000542</guid>
      <pubDate>Thu, 28 Aug 2025 13:00:00 GMT</pubDate>
      <description>SINGAPORE, Aug. 28, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, is pleased to announce it has successfully expanded clinical-scale natural killer (“NK”) cells from cord blood units th</description>
    </item>
    <item>
      <title>CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program</title>
      <link>https://6ix.com/company/cytomed-therapeutics-limited-ordinary-shares/news/cytomed-therapeutics-limited-announces-market-010000886</link>
      <guid isPermaLink="true">https://6ix.com/company/cytomed-therapeutics-limited-ordinary-shares/news/cytomed-therapeutics-limited-announces-market-010000886</guid>
      <pubDate>Tue, 19 Aug 2025 01:00:00 GMT</pubDate>
      <description>SINGAPORE, Aug. 18, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the affordable treatment of blood and solid cancers, is pleased to announce that it entered into an At-the-Market Sales Agreement (the “Sales Agreement”) with R.F. Lafferty &amp; Co., Inc. (the “Agent”), a</description>
    </item>
    <item>
      <title>Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies</title>
      <link>https://6ix.com/company/cytomed-therapeutics-limited-ordinary-shares/news/clinical-trial-milestone-cytomed-therapeutics-140100785</link>
      <guid isPermaLink="true">https://6ix.com/company/cytomed-therapeutics-limited-ordinary-shares/news/clinical-trial-milestone-cytomed-therapeutics-140100785</guid>
      <pubDate>Mon, 21 Jul 2025 14:01:00 GMT</pubDate>
      <description>SINGAPORE, July 21, 2025 (GLOBE NEWSWIRE) -- Further to our announcement filed on Form 6-K on November 20, 2024, CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the affordable treatment of blood and solid cancers, is pleased to announce the successful completion of dose level 1 for its first-i</description>
    </item>
    <item>
      <title>CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates</title>
      <link>https://6ix.com/company/cytomed-therapeutics-limited-ordinary-shares/news/cytomed-therapeutics-reports-full-ended-200500533</link>
      <guid isPermaLink="true">https://6ix.com/company/cytomed-therapeutics-limited-ordinary-shares/news/cytomed-therapeutics-reports-full-ended-200500533</guid>
      <pubDate>Mon, 28 Apr 2025 20:05:00 GMT</pubDate>
      <description>SINGAPORE, April 28, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived, cell-based allogeneic immunotherapies without engaging in separate activities such as contract manufacturing, contract research, medical device development, or diagnostics, today announced its full-year ended December 31, 2024</description>
    </item>
    <item>
      <title>CytoMed Therapeutics announces Chairman’s Letter to the Company’s shareholders</title>
      <link>https://6ix.com/company/cytomed-therapeutics-limited-ordinary-shares/news/cytomed-therapeutics-announces-chairmans-letter-to-the-companys-shareholders</link>
      <guid isPermaLink="true">https://6ix.com/company/cytomed-therapeutics-limited-ordinary-shares/news/cytomed-therapeutics-announces-chairmans-letter-to-the-companys-shareholders</guid>
      <pubDate>Thu, 06 Feb 2025 05:00:00 GMT</pubDate>
      <description>SINGAPORE, Feb. 06, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”) today released a letter to shareholders</description>
    </item>
    <item>
      <title>CytoMed Therapeutics signs Business &amp; Research Collaboration Agreement with India’s SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical tr...</title>
      <link>https://6ix.com/company/cytomed-therapeutics-limited-ordinary-shares/news/cytomed-therapeutics-signs-business-and-research-collaboration-agreement-with-indias-sunact-cancer-institute-private-limited-to-advance-use-of-allogeneic-off-the-shelf-gamma-delta-t-cells-for-treatment-of-solid-cancers-in-a-proposed-phase-2-clinical-tr</link>
      <guid isPermaLink="true">https://6ix.com/company/cytomed-therapeutics-limited-ordinary-shares/news/cytomed-therapeutics-signs-business-and-research-collaboration-agreement-with-indias-sunact-cancer-institute-private-limited-to-advance-use-of-allogeneic-off-the-shelf-gamma-delta-t-cells-for-treatment-of-solid-cancers-in-a-proposed-phase-2-clinical-tr</guid>
      <pubDate>Mon, 06 Jan 2025 05:00:00 GMT</pubDate>
      <description>CytoMed Therapeutics signs Business &amp; Research Collaboration Agreement with India’s SunAct Cancer Institute Private Limited to advance use of allogeneic</description>
    </item>
    <item>
      <title>Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies</title>
      <link>https://6ix.com/company/cytomed-therapeutics-limited-ordinary-shares/news/update-on-clinical-milestone-cytomed-therapeutics-announces-first-patient-dosed-in-its-first-in-human-phase-i-clinical-trial-of-allogeneic-car-gamma-delta-t-cell-therapy-in-patients-with-advanced-solid-tumours-or-haematological-malignancies</link>
      <guid isPermaLink="true">https://6ix.com/company/cytomed-therapeutics-limited-ordinary-shares/news/update-on-clinical-milestone-cytomed-therapeutics-announces-first-patient-dosed-in-its-first-in-human-phase-i-clinical-trial-of-allogeneic-car-gamma-delta-t-cell-therapy-in-patients-with-advanced-solid-tumours-or-haematological-malignancies</guid>
      <pubDate>Wed, 20 Nov 2024 05:00:00 GMT</pubDate>
      <description>SINGAPORE, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Further to an announcement on October 7, 2024, CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or</description>
    </item>
    <item>
      <title>CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant</title>
      <link>https://6ix.com/company/cytomed-therapeutics-limited-ordinary-shares/news/cytomed-therapeutics-first-in-human-phase-i-angelica-clinical-trial-using-its-patented-donor-allogeneic-chimeric-antigen-receptor-t-cell-car-t-cell-against-blood-and-solid-tumors-received-co-funding-support-from-the-nmrc-clinical-trial-grant</link>
      <guid isPermaLink="true">https://6ix.com/company/cytomed-therapeutics-limited-ordinary-shares/news/cytomed-therapeutics-first-in-human-phase-i-angelica-clinical-trial-using-its-patented-donor-allogeneic-chimeric-antigen-receptor-t-cell-car-t-cell-against-blood-and-solid-tumors-received-co-funding-support-from-the-nmrc-clinical-trial-grant</guid>
      <pubDate>Mon, 07 Oct 2024 04:00:00 GMT</pubDate>
      <description>Completion of cash acquisition of licenced cord blood bank expanding CytoMed’s strategy to cord blood-derived biologics through its subsidiary, LongevityBank</description>
    </item>
    <item>
      <title>CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed’s strategy to cord blood-derived biologics through subsidiary, LongevityBank</title>
      <link>https://6ix.com/company/cytomed-therapeutics-limited-ordinary-shares/news/cytomed-therapeutics-completes-cash-acquisition-of-cord-blood-banking-licence-and-assets-expanding-cytomeds-strategy-to-cord-blood-derived-biologics-through-subsidiary-longevitybank</link>
      <guid isPermaLink="true">https://6ix.com/company/cytomed-therapeutics-limited-ordinary-shares/news/cytomed-therapeutics-completes-cash-acquisition-of-cord-blood-banking-licence-and-assets-expanding-cytomeds-strategy-to-cord-blood-derived-biologics-through-subsidiary-longevitybank</guid>
      <pubDate>Thu, 03 Oct 2024 04:00:00 GMT</pubDate>
      <description>SINGAPORE, Oct. 03, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company</description>
    </item>
    <item>
      <title>CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates</title>
      <link>https://6ix.com/company/cytomed-therapeutics-limited-ordinary-shares/news/cytomed-therapeutics-reports-six-months-ended-june-30-2024-financial-results-and-provides-clinical-and-corporate-updates</link>
      <guid isPermaLink="true">https://6ix.com/company/cytomed-therapeutics-limited-ordinary-shares/news/cytomed-therapeutics-reports-six-months-ended-june-30-2024-financial-results-and-provides-clinical-and-corporate-updates</guid>
      <pubDate>Mon, 30 Sep 2024 04:00:00 GMT</pubDate>
      <description>Conference call via Zoom is scheduled for October 8, 2024 at 9 a.m. ET (9 p.m. SGT)</description>
    </item>
    <item>
      <title>CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers</title>
      <link>https://6ix.com/company/cytomed-therapeutics-limited-ordinary-shares/news/cytomed-therapeutics-acquires-cord-blood-banking-licence-and-assets-to-entrench-its-strategy-in-allogeneic-off-the-shelf-donor-derived-gamma-delta-gd-t-cells-technology-for-solid-and-liquid-cancers</link>
      <guid isPermaLink="true">https://6ix.com/company/cytomed-therapeutics-limited-ordinary-shares/news/cytomed-therapeutics-acquires-cord-blood-banking-licence-and-assets-to-entrench-its-strategy-in-allogeneic-off-the-shelf-donor-derived-gamma-delta-gd-t-cells-technology-for-solid-and-liquid-cancers</guid>
      <pubDate>Wed, 17 Jul 2024 04:00:00 GMT</pubDate>
      <description>Another Patent Granted for CytoMed&amp;apos;s Allogeneic Induced Pluripotent Stem Cell (“iPSC”)-derived Hybrid Gamma Delta Natural Killer T (γδ NKT) cells</description>
    </item>
  </channel>
</rss>